The possible role of beta-carotene as a protective nutrient
against cancer is reviewed. Human prospective and retrospective studies strongly indicate that beta-carotene protects against lung cancer and probably against stomach cancer. It may also be protective against cancer of the ovary, cervix, breast and other cancers, but not the colon or rectum.
The protective factor appears to be beta-carotene itself, rather than total vitamin A.. Experiments using a variety of animal models also show that beta-carotene is anticarcinogenic and appears to act at several stages of the process. Possible mechanisms of action are discussed, namely that it must first be converted to vitamin A, that it alters carcinogen metabolism, that it is an anti-oxidant and that it enhances the immune defenses. of the preventive effect of beta-c~~~__cQ~fr9m_~tudie$-on -=hQ:rnan~Wl-t1i ai1d wIthout -'-Such-evidence, more often than not, presents serious problems of.interpretation (3) .
INTRODUCTION
FE~que,ntly, the parameter measured i~diet:ary tot"1g=-~vitamin A, (ie.
retinol pl'us---beta~-carotene).
Howe'ver, retinol and. its-analogues ,.,~-!so have anti-carcfnogenic properties (4) (5) (6) Table   1) . The evidence strongly suggests that persons' wi-th a low intake of beta-carotene are at a 30 to 220% higher risk than otherwise similar people whose intake is relatively high (9,12.13,15-23 tRelative risk is presented so that risk in group with highest intake or blood levcl is 1.0, case-control difference is intake or. blood level in cases relative to controls. OControls not matched for smokini. §NS. not si~nificant, carotene was protective in Anglos who were ex-smokers rather than in hispanlcsor current smokers. **Relationship seen in ttEssentially an index flflResults inconsistent men but not women. of beta-carotene. between soxes, cases had a much lower intake of vitamin A fromsupple~ents.
m co 'I that shows the (9, 16, 22, 23) .
With the exception of one study (18), a low beta-carotene intake is frequently associated with stomach cancer ( Table 2) . Hirayama (28) reported from Japan that in areas where consumption of yellow and/or green vegetables is high, mortality rates for . stomach cancer tend to be low «r == -0.389, P < 0.05).
As with lung canCer the true protective factor is more likely to be beta-carotene than total vitamin A. Thus, Stehr (27) .)
There is no evidence that beta-carotene has a significant role in human colorectai cancer ( Table  2) . The detailed analysis carr"lec]:-out--by -Kun.e.-et--ar;- ( 29) indicated that the increased risk associated with a reduced beta-carotene intake is an artifact aQsil}g_.frol'!! the. close relationship between beta-_ca~oterie--and vegetables.
--.
- . compared with B12'controls (31) .
No association was seen with dietary carotene.
FEMALE REPRODUCTIVE CANCERS
Ovarian cancer appears to be associated with a low intake of beta-carotene, but only in younger women (Table 3) .
Beta-carotene also. seems protective. against breast cancer, particularly in past.:menopausalwo-m-en (Table-- and Milan O,l$tudies report that dietary beta-carotene had a strong inverse relationship with risk.
The Milan study--iI;;
probably-t.~most~reliable report due to-its size, its focus on beta-carotene, and its allowance for the numerous confounding variables. It also showed an absence of a relationship for dietary retino),. Thus, a low beta-carotene-intake is probaoly-a.r"i"sk-factor--;-but this requires further investigation. (Table 4 ). Thus there are two studies in the u.s. which have indicated that a high intake of vitamin A may actually be a risk factor (38, 39) whereas another study in Japan suggests that yellow and/or green vegetables are protective (21).
There is_limitedLevidence that be~~oten~may be protective against cancer of the larynx, tongue, esophagus and bladder ( Table  5 ) but in each case the confounding effects of other factors such as retinol and vitamin C needs elucidating (13, 18, (40) (41) (42) .
EXPERIMENTAL TUMORS
Beta-carotene has demonstrated a preventive action against a variety of tumor types ( Table 5 ). We (45) recently showed that in mice treated with 1,2-dimethylhydrazine (DMH) beta-carotene causes a fall in tumor incidence by about half (96% for adenocarcinomas, ,40% for adenomas).
Tumor multiplicity was similarly reduced. Mouse mortality, measured from the time when tumors were already present, also fell by about half.
The dose of beta-carotene (20 mg/kg diet) is equivalent to about 150 to 300 g carrots per 3000 cals, ahd is therefore in the nutritionally relevant range. It is the lowest dose yet shown to be anti-carcinogenic. However, a s~milar-experil!\~_t on rats show~~_n9__r~~c~~the yield of tumo.a>--.in-thecolon~and-smalT--intestine (46).
There are several elifferences -betweenth~s experimelit---ana ours, which might account for these contradictory findings.
The rat study used a 500 times higher dose of beta-carotene, the species difference, and their control group had a tumor incidence of 100% (versus 74% in our study).
Several studies (47-50) have provided firm evidence that beta-carotene prevents skin tumors (Table 5 ).
In each case thẽ~~_ leY~L-of beta~arotene-u~d was many times greater than can be ol2..tained from nat~.al---foods.
It (57). Other studies listed in Table Shave indicated that beta-carotene can be effective when given before the carcinogen (54), after the carcinogen (53) or else after tumors are already present (48) .
The experiments using an oncogenic virus (5S) and a transplantable tumor (56) point to a late stage effect.
In our mouse colon study beta-carotene did not affect DMH induced colon mucosal hyperplasia, suggesting that the protective effect occurred during promotion (45) .
In summary, beta-carotene appears to block the initiation, promotion and subsequent development of tumors.
There are several possible mechanisms to account for the anti-carcinogenicity of beta-car9ten~.. It. may require. prior co-nv;ersiOn-to=_~~tinol. However, this is a do"Ubtful-m6de 'of--action in.
.
either-humans
or--experimental animals.
-As-noted-' earlier, studies on human lung cancer strongly indicate that the protective action of beta-carotene is not shared by retinal (9, 12, 13, (15) (16) (17) (18) (19) (20) (21) (22) (23) . Weaker evidence suggests that this is also the case-in stomach and cervical cancer (12,13,18,27,28,jS-37) . Further experiments on :r:ats.us'ing_.J:"e.t.inoLo~ §!_~inoids have. seen, onlya much weaker protective e.ff.ect (58) (59) (60) (61) . Similarly, the preventive acti'on of beta-carotene against DMBA induced submandibular gland tumors of rats (Table 5) is not shared by 13-cis-retinoic acid (62) .
The study reporting that beta-carotene prevented DMBA ind~~edLin vitro transformation of mouse mammary cells also observed that there was no accumulation of retinol (57), and thus beta-carotene itself seems to be the active compound. Canthaxanthin is such a carotenoid and does indeed protect mice against skin tumor formation' (4 T, 49) . ' the immune response of rat colorectal tissue (Gg), increases the cytotoxicity of macrophages towards hamster tumor cells (70) and enhances thymic function, particularly lymphocyte production (55). Beta-carotene also influences human interferon action, an effect opposite in direction to that of retinoic acid (71,72).
COMMENT
The ideal strategy in the war on cancer is to learn how to prevent it as well as cure it. In this regard beta-carotene is "well on its way to being an important weapon. It appears to help prevent several cancers, particulary of the lung. That it apparently achieves much of its effectiveness in late carcinogenesis is particularly valuable. There is ample justification to recommend that the general population emphasizes green and yellow vegetables.
Quite apart from beta-carotene, they also have many nutritional virtues.
While it is possible that.-beta-carotene -supp1ementation~may
have potential value t9-_4:!-.g"!1-risk individuals, there is still much to be le"arned before recommemdation-can be made for the carotenoid supplementation to prevent cancer. Animal experiments need to be extended to cover more organ systems (very little has been done on animal models of major human cancers We would urge anyone contemplating such an investigation to study the papers by Peto et al. (l)! Peto (74) and Palgi (3).
Two primary prevention trials employing beta-carotene supplements are currently in progress, one with physicians in the U.S .A. (75) and another. on smokers in Finland (76). Hopefully, the results will prove to be highly rewarding. 10. 11.. 
